In a waiting room that could pass for any specialty clinic, patients are paying five figures for a procedure that sounds like science fiction: having their blood replaced, one tube at a time, in hopes of turning back the clock on aging.
Therapeutic plasma exchange, or TPE, has been used in medicine for decades to treat autoimmune disorders and certain neurological conditions. Now a niche of longevity clinics is offering it to healthy adults over 50 as a method to reduce biological age. A peer-reviewed study from the Buck Institute for Research on Aging, published in August 2025 in Aging Cell, provides the most rigorous data yet supporting the approach [1]. The question is what that data actually shows, and where the uncertainties lie.
Disclosure: Study co-author Dobri Kiprov is co-founder and chief scientific officer of Circulate Inc., a longevity clinic offering TPE. Eric Verdin is president of the Buck Institute for Research on Aging, where the study was conducted.
The Study That Changed the Conversation
The Fuentealba et al. trial is notable for its design: randomized, placebo-controlled, and single-blinded, with 42 participants split across different TPE regimens [1]. Participants received either bi-weekly TPE combined with intravenous immunoglobulin (IVIG), bi-weekly TPE alone, monthly TPE, or a placebo procedure. The primary goal was assess safety. The secondary goal was whether TPE measurably altered biological age markers.
The results were statistically significant. Across 15 epigenetic clocks, TPE-treated participants showed biological age rejuvenation compared to the placebo group, with a false discovery rate below 0.05 [1]. The bi-weekly TPE-IVIG protocol produced the strongest effects, reversing age-related immune decline and modulating proteins linked to chronic inflammation [1].
That is a meaningful finding. Epigenetic clocks are not a single test but a collection of biomarkers that estimate biological age based on DNA methylation patterns. Seeing consistent changes across 15 independent clocks in a placebo-controlled trial is the kind of signal that warrants serious attention.
Whether the magnitude of effect translates to the specific figures cited in longevity circles is less clear from the published data. What is clear is that something biologically measurable happened.
How TPE Works
TPE separates blood into its components using a cell separator. Plasma, which carries signaling proteins, cytokines, and accumulated age-related molecules, is removed. The cellular components are returned to the patient along with an albumin solution to replace the extracted volume. The process takes about one to two hours and requires IV access in both arms.
The mechanism appears to involve dilution of autoregulatory proteins rather than infusion of young plasma. A landmark 2020 mouse study found that replacing old plasma with a saline-albumin solution was sufficient to rejuvenate brain, liver, and muscle tissue, matching or exceeding effects previously seen with young blood exposure [2]. A single TPE in humans produced functional blood rejuvenation in that study as well [2]. The implication: it is not what you add, but what you remove.
Safety Profile
The trial data suggest TPE is well-tolerated in this context. Only two adverse events led to discontinuation across all treatment arms [1]. Long-term TPE was deemed safe, which matters given that the procedure must be repeated to maintain any effect. Common side effects include temporary citrate-induced numbness, mild hypotension, and fatigue. More serious complications like infections or vein damage are possible but rare in clinical settings.
What It Costs
Longevity clinics offering TPE typically price programs between $5,000 and $15,000 [5]. Since insurance covers plasma exchange only for FDA-approved indications, patients pursuing it for longevity purposes pay out of pocket. A full protocol involves multiple sessions over weeks or months, and maintenance schedules remain undefined.
The Regulatory Landscape
The FDA issued a warning in 2019 against young blood plasma transfusions marketed for anti-aging purposes, noting there is no proven clinical benefit for such use [4]. Ambrosia, one of the more prominent companies in that space, shut down after the warning [4]. TPE longevity programs operate differently: they use an FDA-cleared procedure off-label for a non-approved purpose. This is legal, though it places the financial and medical risk entirely on the patient.
Where the Evidence Still Falls Short
It is worth being clear about the limits. A 2026 critical review of plasma-based rejuvenation strategies notes that existing clinical trials do not yet provide sufficient evidence for therapeutic efficacy in extending healthspan or lifespan [3]. The gap between biomarker changes and meaningful clinical outcomes remains substantial.
The longest controlled human study to date covers months, not years. Whether the biological age reductions persist, grow, or fade after treatment stops is unknown. The optimal dose, schedule, and long-term safety profile in healthy older adults also remain undetermined. Animal models have historically overpromised on longevity interventions, and the mouse-to-human translation gap in geroscience is well-documented.
That does not mean the findings are invalid. It means the field is early, and the excitement should be proportional to the evidence.
The Bottom Line
TPE has moved from animal studies and anecdotal reports into a randomized, controlled human trial with measurable signals. For the right patient, one with realistic expectations and the resources to pursue an unproven intervention, it may hold appeal. But the science is still catching up to the marketing, and anyone considering TPE for longevity purposes should understand exactly how thin the evidence base remains.
The question is not whether TPE does something to biological age markers. The trial data suggest it does. The question is whether those marker changes translate into meaningful differences in how we age, how long we live, or how well we function in later life. That question has not been answered yet.